Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. LMNL

Healthcare Biotechnology
Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Liminal BioSciences Inc.
Bullboard Posts
User Avatar Image
(0)
•••
Comment by joe9999on Dec 15, 2017 10:20am
225 Views
Post# 27164047

RE:don't expect pl to deliver any deal with big pharma

RE:don't expect pl to deliver any deal with big pharma
edrose wrote: anytime soon,he still think good data eg/ like ipf will increase sp all this good research if not monetized will NOT get the sp higher we have seen it several times in 2017 and don't forget jan 2016 our sp was 3.60  another harsh reality some people say i'm negative no i just look at numbers and how this co. is beeing managed on business side and i don't agree



" i just look at numbers and how this co. is beeing managed on business side and i don't agree..."

JUST ONE ANSWER:  SELL ....


Bullboard Posts
Dealroom for high-potential pre-IPO opportunities